Review
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastrointest Oncol. Jun 15, 2013; 5(6): 102-112
Published online Jun 15, 2013. doi: 10.4251/wjgo.v5.i6.102
Table 2 European Organization for Research and Treatment of Cancer metabolic response criteria for tumors evaluated with positron emission tomography
Complete metabolic responseComplete resolution of [18F]-FDG uptake within the tumor volume indistinguishable from surrounding normal tissue
Partial metabolic responseReduction of a minimum of 15%-25% in tumor [18F]-FDG SUV after one cycle of chemotherapy Reduction of a minimum of > 25% in tumor [18F]-FDG SUV after more than one treatment cycle
Progressive metabolic diseaseIncrease in [18F]-FDG tumor SUV > 25% within the tumor region, visible increase in the extent of [18F]-FDG tumor uptake (> 20% in the longest dimension) Appearance of new [18F]-FDG uptake.
Stable metabolic diseaseIncrease in tumor [18F]-FDG SUV < 25%, decrease of < 15%. No visible increase in extent of [18F]-FDG tumor uptake (< 20% in the longest dimension)